Wednesday, September 18, 2024

Kimberly R. Kras

1 POSTS 0 COMMENTS
Kimberly Kras earned her Ph.D. in Criminology and Criminal Justice from the University of Missouri-St. Louis where she researched the experience of reentry for individuals convicted of sexual offenses and other issues related to offender reentry including housing, employment, and social support. Prior to coming to UMass Lowell, Kras was a Postdoctoral Research Fellow at George Mason University where she worked on projects pertaining to the implementation of evidence-based practices in community corrections agencies, as well as developing curricula translating research into practice for corrections practitioners. Kras' research focuses on the offender experience of reentry in a life course framework and how these experiences can inform evidence-based practices in probation and parole.

POPULAR

Norway reaches historic milestone as electric vehicles outnumber petrol cars for the first time

Norway’s rapid transition to electric vehicles, a global first, shows the impact of policy incentives and ambitious climate goals, setting the pace for the rest of the world.

Trump-appointed judges continue assault on workers’ rights by undermining NLRB

In a move that could reshape labor rights across the country, these judges are granting preliminary injunctions to companies that argue the NLRB’s structure violates the U.S. Constitution.

Sisyphus Trump maniacally replays 2015, with repeated, inflammatory media blitzes. But that gambit...

How many unforced errors—the Arlington cemetery mess, JD Vance, fake Ohio pet-napping and Loomer—confirm Trump as monumental scatterbrain?

Forests thrive when Indigenous people have legal stewardship of their land

The fate of intact forests is closely linked to that of Indigenous peoples.

Bernie Sanders calls out Big Pharma over exorbitant drug prices: Novo Nordisk’s $900+...

As Novo Nordisk rakes in billions, Sen. Bernie Sanders and public health advocates demand answers on why U.S. patients are charged sky-high prices for life-saving drugs like Ozempic while generics could sell for a fraction of the cost.